Feel free to click on the bold blue text within the article to gain complimentary access to the latest research and development updates regarding the drugs discussed. Junshi Biosciences has officially declared its intention to showcase clinical research outcomes for a range of innovative products at the 2025 Annual Meeting of the European Society for Medical Oncology Asia, scheduled to take place in Singapore from December 5th to 7th. Notably, the anti-Claudin 18.2 (CLDN18.2) ADC drug, JS107, has earned a spot in the Latest Breakthrough Abstract category and will, for the first time, present updated findings from its Phase I clinical trial targeting advanced solid tumors through an oral presentation. Additionally, data from the Phase I clinical trial of the anti-PD-1/VEGF bispecific antibody, JS207, will be unveiled, with the drug currently progressing through multiple Phase II clinical trials. Furthermore, the most recent data from numerous clinical trials involving toripalimab will be showcased in diverse formats, highlighting Junshi Biosciences' accomplishments in exploration and its research prowess within the realms of immuno-combination therapies and innovative treatments. Disclaimer: This article serves solely for informational exchange and does not constitute an endorsement or recommendation for any specific treatment plan. For expert medical advice, please consult a qualified healthcare institution.